Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:43:39 EDT Thu 16 May 2024
Enter Symbol
or Name
USA
CA



Q:STOK - STOKE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
STOK - Q2.013.71·14.630.514.03-0.10-0.7762.710,4137,27314.10  14.39  13.9116.3999  3.3518:15:06May 0615 min RT 2¢

Recent Trades - Last 10 of 7273
Time ETExPriceChangeVolume
18:15:06Q14.03-0.101
17:52:27Q14.03-0.101
16:03:12Q14.03-0.10186,198
16:02:18Q14.03-0.101,561
16:01:45Q14.03-0.10216
16:00:07Q14.03-0.107,100
16:00:07Q14.03-0.1091,838
16:00:04Q14.03-0.104,860
16:00:04Q14.03-0.101,744
16:00:04Q14.03-0.102

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-06 07:00U:STOKNews ReleaseStoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
2024-04-29 08:00U:STOKNews ReleaseStoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
2024-04-17 08:00U:STOKNews ReleaseStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
2024-04-04 16:30U:STOKNews ReleaseStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-27 23:40U:STOKNews ReleaseStoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
2024-03-26 16:07U:STOKNews ReleaseStoke Therapeutics Announces Proposed Public Offering
2024-03-25 16:01U:STOKNews ReleaseStoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-25 16:01U:STOKNews ReleaseStoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
2024-01-17 16:30U:STOKNews ReleaseStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-01-08 08:00U:STOKNews ReleaseStoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
2024-01-04 16:30U:STOKNews ReleaseStoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-01 09:00U:STOKNews ReleaseStoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
2023-11-21 08:00U:STOKNews ReleaseStoke Therapeutics to Present Data from the Company ¢ € ™s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
2023-11-07 07:00U:STOKNews ReleaseStoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
2023-10-17 16:30U:STOKNews ReleaseStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-09-21 08:00U:STOKNews ReleaseStoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
2023-09-20 16:30U:STOKNews ReleaseStoke Therapeutics Appoints Ian Smith to its Board of Directors
2023-09-05 07:00U:STOKNews ReleaseStoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
2023-08-07 07:00U:STOKNews ReleaseStoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
2023-08-02 08:00U:STOKNews ReleaseStoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference